Lead Product(s) : Entinostat,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Experimental Drug that Boosts Immunotherapy Shows Promise in Bladder Cancer Study
Details : When treated with entinostat in combination with immunotherapy, two-thirds of mice had a complete disappearance of their tumors and none of the mice had relapse of their tumors when taken off the treatment.
Brand Name : MS-275
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2021
Lead Product(s) : Entinostat,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2020
Lead Product(s) : Entinostat,Exemestane,Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Citigroup
Deal Size : $115.0 million
Deal Type : Public Offering
Details : The Company's lead product candidate, entinostat, a class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combination with several approved PD-1...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 12, 2020
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Citigroup
Deal Size : $115.0 million
Deal Type : Public Offering
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Details : Syndax Pharmaceuticals is on track to file for regulatory approval in 2020 and to become a fully-integrated oncology company with the launch of entinostat in HR+ breast cancer expected in 2021.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2020
Lead Product(s) : Entinostat,Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?